Business Context and Reporting Period
This Form 8-K was filed by Genprex, Inc. on February 6, 2020. The report addresses a specific corporate event regarding the company's listing status on the Nasdaq Stock Market.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the stock price performance required for regulatory compliance:
- Stock Price Compliance: The closing bid price of the Company's common stock exceeded $1.00 per share for the period from January 21, 2020, to February 3, 2020.
Material Changes
The primary material change reported is the resolution of a listing deficiency:
- Nasdaq Compliance: On February 4, 2020, the Company received written notification from the Nasdaq Listing Qualifications Staff confirming it has regained compliance with the $1.00 minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
- Status: The matter regarding the minimum bid price deficiency is now closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or discussion of new risks or contingencies. The document is strictly a notification of the restoration of listing compliance.
Investor Verification Checklist
- Verify the current trading status of Genprex, Inc. (GNPX) on the Nasdaq Capital Market.
- Confirm the stock price history between January 21, 2020, and February 3, 2020, to validate the compliance period.
- Review the attached Press Release (Exhibit 99.1) for any additional context not included in the 8-K text.